Skip to main content
. Author manuscript; available in PMC: 2014 Feb 8.
Published in final edited form as: Eur Respir J. 2010 Jan 28;36(3):630–637. doi: 10.1183/09031936.00160209

FIGURE 2.

FIGURE 2

Effect of varying concentrations of the mitogen-activated protein kinase kinase (MEK) inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophe-nylthio]butadiene). The difference (Δ) in force-fluctuation-induced relengthening (FFIR) was compared to that of acetylcholine-contracted canine tracheal smooth muscle strips that received vehicle alone (n=14). Data are presented as mean ± SEM. MEK inhibition modulates FFIR in a concentration-dependent manner (p <0.001 (n=6 per concentration); ANOVA). *: p<0.05 versus no drug treatment; # : p<0.05 versus 0, 3 and 15 μM U0126.